SEC Form 3 FORM 3

UNITED STATES SECURITIES AND EXCHANGE

COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Rackliffe Philip</u>	2. Date of B Requiring S (Month/Day 07/01/202	Statement y/Year)	3. Issuer Name and Ticker or Trading Symbol <u>GE HealthCare Technologies Inc.</u> [GEHC]					
(Last) (First) (Middle)			4. Relationship of Reporting Issuer (Check all applicable)	Person(s) to		 5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person 		
500 W. MONROE STREET (Street) CHICAGO IL 60661 (City) (State) (Zip)	_				specify (
Table I - Non-Derivative Securities Beneficially Owned								
1. Title of Security (Instr. 4)			2. Amount of Securities Beneficially Owned (Instr. 4)	3. Owne Form: D (D) or Ir (I) (Instr	Direct Ov Idirect		ature of Indirect Beneficial lership (Instr. 5)	
Common Stock, par value \$0.01 per share			13,117 ⁽¹⁾⁽²⁾					
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)								
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversio or Exercis Price of	e Form:	6. Nature of Indirect Beneficial Ownership (Instr.	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Direct (D) or Indirect (I) (Instr. 5)	5)	
Employee Stock Option (right to buy)	(3)	02/01/2033	Common Stock, par value \$0.01 per share	7,838	70.01	D		
Employee Stock Option (right to buy)	(4)	03/01/2033	Common Stock, par value \$0.01 per share	4,631	75.3	D		
Employee Stock Option (right to buy)	(5)	03/01/2034	Common Stock, par value \$0.01 per share	3,834	92.72	D		

Explanation of Responses:

1. Consists of awards of: (i) 9,217 restricted stock units with respect to GE HealthCare Technologies Inc. ("GE HealthCare") common stock, granted on September 1, 2022, of which 50% will vest on September 1, 2024 and 50% will vest on September 1, 2025; (ii) 892 restricted stock units with respect to GE HealthCare common stock, granted on February 1, 2023, of which 50% will vest on February 1, 2025 and 50% will vest on February 1, 2026; (iii) 1,660 restricted stock units with respect to GE HealthCare common stock, granted on March 1, 2023, of which 33% will vest on September 1, 2024, 33% will vest on September 1, 2025; and 34% will vest on September 1, 2026; and (iv) 1,348 restricted stock units with respect to GE HealthCare common stock, granted on March 1, 2024, of which 33% will vest on September 1, 2026; and (iv) 1,348 restricted stock units with respect to GE HealthCare common stock, granted on March 1, 2024, of which 33% will vest on September 1, 2026; and 34% will vest on September 1, 2026; and 34% will vest on September 1, 2026, and 34% will vest on September 1, 2027.

2. Each restricted stock unit represents the right to receive, at settlement, one share of GE HealthCare common stock.

3. Award of an employee stock option with respect to GE HealthCare common stock, of which 50% will become exercisable on February 1, 2025 and 50% will become exercisable on February 1, 2026.

4. Award of an employee stock option with respect to GE HealthCare common stock, of which 33% will become exercisable on September 1, 2024, 33% will become exercisable on September 1, 2025, and 34% will become exercisable on September 1, 2026.

5. Award of an employee stock option with respect to GE HealthCare common stock, of which 33% will become exercisable on September 1, 2025, 33% will become exercisable on September 1, 2026, and 34% will become exercisable on September 1, 2027.

Remarks:

Exhibit 24.1 - Power of Attorney

<u>/s/ Frank R. Jimenez,</u> <u>General Counsel and</u> <u>Corporate Secretary, as</u> <u>attorney-in-fact</u>

07/01/2024

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Power of Attorney

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of (i) Frank R. Jimenez and (ii) Jenny L. Lauth, signing SINGLY, the undersigned's true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director or holder of ten percent (10%) or more of the registered class of securities of GE HealthCare Technologies Inc. (the "*Company*"), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;

(2) If necessary, submit a Form ID to apply for and obtain EDGAR filing codes in order to file a Form 3 on behalf of the undersigned;

(3) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Form 3, 4 or 5, complete and execute any amendment or amendments thereto and timely file such forms or amendments with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

* * * * *

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 12th day of June 2024.

By: <u>/s/ Philip Rackliffe</u> Name: Philip Rackliffe

[Signature Page to Power of Attorney (Forms 3, 4 & 5)]